GLP-1 Weekly News
Every week we summarise the GLP-1 stories that actually matter — neutrally, with a link to the original source and to our evergreen explainer on each topic. Nothing here is influenced by advertisers.
- September 4, 2026
GLP-1 News — Week of August 31, 2026
Mounjaro adds a heart‑protection label as Saxenda’s exit clock starts and courts back FDA’s clampdown on compounded GLP‑1s.
- August 28, 2026
GLP-1 News — Week of August 24, 2026
Lilly cracks down on black‑market retatrutide as liraglutide shortages persist and Medicare's new GLP‑1 coverage rules keep reshaping access.
- August 21, 2026
GLP-1 News — Week of August 17, 2026
FDA quietly lays groundwork for future GLP-1 generics while safety concerns around compounded products stay in focus.
- August 7, 2026
GLP-1 News — Week of August 3, 2026
Medicare’s GLP-1 Bridge and state Medicaid moves made access rules, not new drugs, the story this week.
- July 31, 2026
GLP-1 News — Week of July 27, 2026
Medicare's GLP-1 Bridge moves from policy to real-world access, while a potent new triple-agonist drug edges closer to market.
- July 24, 2026
GLP-1 News — Week of July 20, 2026
FDA tightens controls on compounded GLP-1 ingredients as new safety data and policy shifts reshape access options.
- July 23, 2026
GLP-1 News — Week of July 6, 2026
A quiet week for GLP-1 news: no new FDA actions, but Lilly updates supply, pricing, and compounding warnings for tirzepatide.
- July 23, 2026
GLP-1 News — Week of July 13, 2026
Tirzepatide supply normalizes, compounding risks rise, and new data sharpen expectations for GLP-1 benefits and long-term use.
- June 7, 2026
GLP-1 News — Week of June 1, 2026
PBM moves reshape GLP-1 access as Cigna cuts coverage and CVS pivots toward multi-drug obesity formularies.